Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Study Purpose
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also make tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. This randomized phase I/II trial is studying the best dose of dasatinib and to see how well it works compared with a placebo when given together with radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Pre-registration
Inclusion Criteria:
1. Central Pathology Review- - Central pathology review submission.
Inclusion Criteria:
1. Age ≥ 18 years. 2. Histological Confirmation of Glioblastoma- - Histologically confirmed newly diagnosed glioblastoma (GBM) (grade 4 astrocytoma) as determined by pre-registration central pathology review.
- - Measurable or evaluable disease by gadolinium MRI or contrast CT scan.
- - Absolute neutrophil count (ANC) ≥ 1500/mm3.
- - Platelet count ≥ 100,000/mm3.
- - Hemoglobin > 9.0 g/dL.
- - Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) - SGOT (AST) ≤ 2.5 x ULN.
- - Creatinine ≤ 1.5 x ULN.
- - INR ≤ 1.5.
- - Negative urine or serum pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only.
- - Patient must provide written informed consent.
- - Patient must be willing to return to Alliance enrolling institution for follow-up.
- - Patient must be willing to provide tissue samples for research purposes.
- - Patient must be willing to comply with antibiotic prophylaxis with trimethoprim/sulfamethoxazole, pentamidine or dapsone.
- - Patient must be willing to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study treatment.
- - Patient must have the ability to take oral medication (dasatinib must be swallowed whole).
- - Phase II patients only: Patients must be willing and able to complete QOL questionnaires independently or with the help of a caregiver.
- - Patient must be willing to forego other cytotoxic and non-cytotoxic drug therapy against the tumor while being treated with dasatinib and temozolomide.
Exclusion Criteria:
1. Pregnancy, Nursing and Required Contraception- - Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: - Pregnant women.
- - Nursing women.
- - Men or women of childbearing potential who are unwilling to employ adequate contraception throughout study treatment and for at least 12 weeks after study drug is stopped.
- - Received any prior radiotherapy or chemotherapy for any CNS neoplasm (hormones, vitamins and growth factors are not considered chemotherapy for the purposes of this study.
- - Prior surgeries for any CNS neoplasms, other than surgery related to the current GBM diagnosis.
- - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
- - History of bleeding diathesis.
- - Current use of chronic systemic anticoagulation therapy that cannot be discontinued (antiplatelet agents, Aspirin) - Current chronic use of NSAIDs which cannot be discontinued.
- - Pleural or pericardial effusion of any grade.
- - Immunocompromised patients (other than that related to the use of corticosteroids) and patients known to be HIV positive and currently receiving antiretroviral therapy.
- - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- - Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
- - Other active malignancy ≤ 5 years prior to registration.
- - Myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
- - Diagnosed congenital long QT syndrome.
- - Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) - Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec) - Patients with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration.
- - Patients may not have any clinically significant cardiovascular disease including the following: - Myocardial infarction or ventricular tachyarrhythmia within 6 months.
- - Ejection fraction less than institutional normal.
- - Major conduction abnormality (unless a cardiac pacemaker is present) Note: Patients with any cardiopulmonary symptoms of unknown cause (e.g., shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to ECG to rule out QTc prolongation.
- - New York Heart Association classification ≥ Class II Congestive Heart Failure.
- - Currently taking one of the following medications: - Enzyme inducing anti-convulsants (EIACs) Note: To be eligible, patient must be switched to non-EIAC medications ≥7 days prior to registration.
- - Potent inhibitors of CYP3A4 which cannot be discontinued.
- - Medications known to prolong QT interval which cannot be discontinued or switched.
- - Medications that may possibly prolong QT interval and produce a QTc that is ≥ 60 msec or a QTcF that is ≥ 450 msec.
- - St. John's Wort.
- - H2 blockers or proton pump inhibitors (PPIs), such as famotidine (Pepcid) and omeprazole (Prilosec) respectively, which cannot be discontinued or switched to locally acting agents, such as Maalox, Mylanta and TUMS.
- - Severe allergy to sulfa medications and dapsone and pentamidine.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT00869401 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 1/Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Alliance for Clinical Trials in Oncology |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Nadia N. Laack, MD |
| Principal Investigator Affiliation | Mayo Clinic |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Other, NIH, Industry |
| Overall Status | Completed |
| Countries | United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Brain and Central Nervous System Tumors |
This trial includes a phase I dose-escalation study and a double-blind randomized phase II trial for patients with newly diagnosed glioblastoma multiforme (GBM). Phase I will be a cohort of 3 dose-escalation trial of dasatinib in combination with radiation and concomitant temozolomide. Patients receive concomitant chemotherapy and radiation therapy for cycle one. Patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only dasatinib post cycle 8 treatment until progressive disease, unacceptable adverse events or refusal. Phase II will be a randomized trial with two treatment arms. Patients will be randomized at the time of registration at a ratio of 1:2 respectively to either standard therapy arm (continuous daily placebo prior, during and after standard radiotherapy/temozolomide followed by temozolomide. For more information please see the Arms section. The primary objectives are listed below. Primary Objectives: 1. To establish a maximum tolerated dose of dasatinib combined with radiation and temozolomide in this patient population (Phase I) 2. To determine the efficacy of dasatinib in combination with radiotherapy and concomitant and adjuvant temozolomide in patients with newly diagnosed glioblastoma, and compare it with the standard of care approach in the treatment of these patients consisting of radiotherapy and temozolomide, followed by adjuvant temozolomide (Phase II) Patients are followed for 5 years post treatment. The study permanently closed to accrual on January 31, 2014.
Arms
Experimental: Group 1 (Phase II) dasatinib + radiation + temozolomide
Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only dasatinib post cycle 8 until progressive disease, unacceptable adverse events or refusal.
Active Comparator: Group 2 (Phase II) placebo + radiation + temozolomide
Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only placebo post cycle 8 until progressive disease, unacceptable adverse events or refusal.
Interventions
Drug: - dasatinib
Given orally
Drug: - temozolomide
Given orally
Other: - placebo
Given orally
Radiation: - radiation therapy
Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Helen and Harry Gray Cancer Center at Hartford Hospital
Hartford, Connecticut, 06102-5037
Status
Address
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Status
Address
John B. Amos Cancer Center
Columbus, Georgia, 31904
Status
Address
Illinois CancerCare - Bloomington
Bloomington, Illinois, 61701
Status
Address
St. Joseph Medical Center
Bloomington, Illinois, 61701
Status
Address
Illinois CancerCare - Canton
Canton, Illinois, 61520
Status
Address
Illinois CancerCare - Carthage
Carthage, Illinois, 62321
Status
Address
Resurrection Medical Center
Chicago, Illinois, 60631
Status
Address
Eureka Community Hospital
Eureka, Illinois, 61530
Status
Address
Illinois CancerCare - Eureka
Eureka, Illinois, 61530
Status
Address
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Status
Address
Illinois CancerCare - Havana
Havana, Illinois, 62644
Status
Address
Illinois CancerCare - Kewanee Clinic
Kewanee, Illinois, 61443
Status
Address
Illinois CancerCare - Macomb
Macomb, Illinois, 61455
Status
Address
Illinois CancerCare - Monmouth
Monmouth, Illinois, 61462
Status
Address
OSF Holy Family Medical Center
Monmouth, Illinois, 61462
Status
Address
BroMenn Regional Medical Center
Normal, Illinois, 61761
Status
Address
Community Cancer Center
Normal, Illinois, 61761
Status
Address
Illinois CancerCare - Community Cancer Center
Normal, Illinois, 61761
Status
Address
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Status
Address
Oncology Hematology Associates of Central Illinois, PC - Ottawa
Ottawa, Illinois, 61350
Status
Address
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
Status
Address
Illinois CancerCare - Pekin
Pekin, Illinois, 61603
Status
Address
Proctor Hospital
Peoria, Illinois, 61614
Status
Address
OSF St. Francis Medical Center
Peoria, Illinois, 61615-7827
Status
Address
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Status
Address
Oncology Hematology Associates of Central Illinois, PC - Peoria
Peoria, Illinois, 61615
Status
Address
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Status
Address
Illinois CancerCare - Peru
Peru, Illinois, 61354
Status
Address
Illinois Valley Community Hospital
Peru, Illinois, 61354
Status
Address
Illinois CancerCare - Princeton
Princeton, Illinois, 61356
Status
Address
Illinois CancerCare - Spring Valley
Spring Valley, Illinois, 61362
Status
Address
Valley Cancer Center
Spring Valley, Illinois, 61362
Status
Address
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Status
Address
Elkhart Clinic, LLC
Elkhart, Indiana, 46514-2098
Status
Address
Michiana Hematology-Oncology, PC - Elkhart
Elkhart, Indiana, 46514
Status
Address
Elkhart General Hospital
Elkhart, Indiana, 46515
Status
Address
St. Francis Hospital Cancer Care Services
Indianapolis, Indiana, 46237
Status
Address
Howard Community Hospital
Kokomo, Indiana, 46904
Status
Address
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Status
Address
Michiana Hematology-Oncology, PC - South Bend
Mishawaka, Indiana, 46545-1470
Status
Address
Saint Joseph Regional Medical Center
Mishawaka, Indiana, 46545-1470
Status
Address
Michiana Hematology Oncology PC - Plymouth
Plymouth, Indiana, 46563
Status
Address
Reid Hospital & Health Care Services
Richmond, Indiana, 47374
Status
Address
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
Status
Address
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Status
Address
Michiana Hematology Oncology PC - La Porte
Westville, Indiana, 46391
Status
Address
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Status
Address
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Status
Address
Medical Oncology and Hematology Associates - West Des Moines
Clive, Iowa, 50325
Status
Address
Mercy Cancer Center - West Lakes
Clive, Iowa, 50325
Status
Address
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
Status
Address
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Status
Address
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Status
Address
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Status
Address
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Status
Address
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Status
Address
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa, 51101
Status
Address
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51102
Status
Address
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
Status
Address
Methodist West Hospital
West Des Moines, Iowa, 50266-7700
Status
Address
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Status
Address
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Status
Address
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Status
Address
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Status
Address
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Status
Address
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Status
Address
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Status
Address
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67901
Status
Address
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Status
Address
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Status
Address
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Status
Address
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67401
Status
Address
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Status
Address
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67208
Status
Address
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Status
Address
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
Status
Address
CCOP - Wichita
Wichita, Kansas, 67214
Status
Address
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Status
Address
Wesley Medical Center
Wichita, Kansas, 67214
Status
Address
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Status
Address
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
Status
Address
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Status
Address
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Status
Address
Lakeland Regional Cancer Care Center - St. Joseph
Saint Joseph, Michigan, 49085
Status
Address
Lakeside Cancer Specialists, PLLC
Saint Joseph, Michigan, 49085
Status
Address
MeritCare Bemidji
Bemidji, Minnesota, 56601
Status
Address
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Status
Address
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Status
Address
Essentia Health - Duluth Clinic
Duluth, Minnesota, 55805-1983
Status
Address
CCOP - Duluth
Duluth, Minnesota, 55805
Status
Address
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
Status
Address
Fairview Southdale Hospital
Edina, Minnesota, 55435
Status
Address
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Status
Address
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Status
Address
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Status
Address
Minnesota Oncology - Maplewood
Maplewood, Minnesota, 55109
Status
Address
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Status
Address
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Status
Address
Humphrey Cancer Center at North Memorial Outpatient Center
Robbinsdale, Minnesota, 55422-2900
Status
Address
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Status
Address
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Status
Address
Coborn Cancer Center
Saint Cloud, Minnesota, 56303
Status
Address
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Status
Address
Park Nicollet Cancer Center
Saint Louis Park, Minnesota, 55416
Status
Address
Regions Hospital Cancer Care Center
Saint Paul, Minnesota, 55101
Status
Address
United Hospital
Saint Paul, Minnesota, 55102
Status
Address
St. Francis Cancer Center at St. Francis Medical Center
Shakopee, Minnesota, 55379
Status
Address
Lakeview Hospital
Stillwater, Minnesota, 55082
Status
Address
Ridgeview Medical Center
Waconia, Minnesota, 55387
Status
Address
Willmar Cancer Center at Rice Memorial Hospital
Willmar, Minnesota, 56201
Status
Address
Minnesota Oncology - Woodbury
Woodbury, Minnesota, 55125
Status
Address
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
Saint Louis, Missouri, 63110
Status
Address
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Status
Address
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Status
Address
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59102
Status
Address
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Status
Address
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Status
Address
St. James Healthcare Cancer Care
Butte, Montana, 59701
Status
Address
Benefis Sletten Cancer Institute
Great Falls, Montana, 59405
Status
Address
St. Peter's Hospital
Helena, Montana, 59601
Status
Address
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Status
Address
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Status
Address
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Status
Address
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, 03301
Status
Address
New Hampshire Oncology - Hematology, PA - Hooksett
Hooksett, New Hampshire, 03106
Status
Address
Lakes Region General Hospital
Laconia, New Hampshire, 03246
Status
Address
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87131-5636
Status
Address
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Status
Address
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Status
Address
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Status
Address
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Status
Address
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
Status
Address
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
Status
Address
MeritCare Broadway
Fargo, North Dakota, 58102
Status
Address
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
Status
Address
Wood County Oncology Center
Bowling Green, Ohio, 43402
Status
Address
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Status
Address
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
Status
Address
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
Status
Address
CCOP - Columbus
Columbus, Ohio, 43215
Status
Address
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Status
Address
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Status
Address
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Status
Address
Grandview Hospital
Dayton, Ohio, 45405
Status
Address
Good Samaritan Hospital
Dayton, Ohio, 45406
Status
Address
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Status
Address
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Status
Address
CCOP - Dayton
Dayton, Ohio, 45420
Status
Address
Grady Memorial Hospital
Delaware, Ohio, 43015
Status
Address
Community Cancer Center
Elyria, Ohio, 44035
Status
Address
Hematology Oncology Center
Elyria, Ohio, 44035
Status
Address
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Status
Address
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Status
Address
Wayne Hospital
Greenville, Ohio, 45331
Status
Address
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Status
Address
Fairfield Medical Center
Lancaster, Ohio, 43130
Status
Address
Lima Memorial Hospital
Lima, Ohio, 45804
Status
Address
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Status
Address
Northwest Ohio Oncology Center
Maumee, Ohio, 43537-1839
Status
Address
Knox Community Hospital
Mount Vernon, Ohio, 43050
Status
Address
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Status
Address
St. Charles Mercy Hospital
Oregon, Ohio, 43616
Status
Address
Toledo Clinic - Oregon
Oregon, Ohio, 43616
Status
Address
Southern Ohio Medical Center Cancer Center
Portsmouth, Ohio, 45662
Status
Address
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
Status
Address
Flower Hospital Cancer Center
Sylvania, Ohio, 43560
Status
Address
Mercy Hospital of Tiffin
Tiffin, Ohio, 44883
Status
Address
Toledo Hospital
Toledo, Ohio, 43606
Status
Address
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
Status
Address
Medical University of Ohio Cancer Center
Toledo, Ohio, 43614
Status
Address
St. Anne Mercy Hospital
Toledo, Ohio, 43623
Status
Address
Toledo Clinic, Incorporated - Main Clinic
Toledo, Ohio, 43623
Status
Address
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373-1300
Status
Address
Fulton County Health Center
Wauseon, Ohio, 43567
Status
Address
Precision Radiotherapy at University Pointe
West Chester, Ohio, 45069
Status
Address
Mount Carmel St. Ann's Cancer Center
Westerville, Ohio, 43081
Status
Address
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
Status
Address
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
Status
Address
Natalie Warren Bryant Cancer Center at St. Francis Hospital
Tulsa, Oklahoma, 74136
Status
Address
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Status
Address
Cancer Centers of the Carolinas - Easley
Easley, South Carolina, 29640
Status
Address
Cancer Centers of the Carolinas - Faris Road
Greenville, South Carolina, 29605
Status
Address
Cancer Centers of the Carolinas - Grove Commons
Greenville, South Carolina, 29605
Status
Address
Greenville Hospital Cancer Center
Greenville, South Carolina, 29605
Status
Address
Cancer Centers of the Carolinas - Eastside
Greenville, South Carolina, 29615
Status
Address
CCOP - Greenville
Greenville, South Carolina, 29615
Status
Address
Cancer Centers of the Carolinas - Greer Medical Oncology
Greer, South Carolina, 29650
Status
Address
Cancer Centers of the Carolinas - Greer Radiation Oncology
Greer, South Carolina, 29650
Status
Address
Cancer Centers of the Carolinas - Seneca
Seneca, South Carolina, 29672
Status
Address
Cancer Centers of the Carolinas - Spartanburg
Spartanburg, South Carolina, 29307
Status
Address
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Status
Address
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Status
Address
Sanford Cancer Center at Sanford USD Medical Center
Sioux Falls, South Dakota, 57117-5039
Status
Address
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Status
Address
Center for Cancer Treatment & Prevention at Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Status
Address
Marshfield Clinic Cancer Care at Regional Cancer Center
Eau Claire, Wisconsin, 54701
Status
Address
Central Wisconsin Cancer Program at Agnesian HealthCare
Fond Du Lac, Wisconsin, 54935
Status
Address
Gundersen Lutheran Center for Cancer and Blood
La Crosse, Wisconsin, 54601
Status
Address
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Status
Address
Saint Joseph's Hospital
Marshfield, Wisconsin, 54449
Status
Address
Marshfield Clinic - Lakeland Center
Minocqua, Wisconsin, 54548
Status
Address
Ministry Medical Group at Saint Mary's Hospital
Rhinelander, Wisconsin, 54501
Status
Address
Marshfield Clinic - Indianhead Center
Rice Lake, Wisconsin, 54868
Status
Address
Marshfield Clinic at Saint Michael's Hospital
Stevens Point, Wisconsin, 54481
Status
Address
Saint Michael's Hospital Cancer Center
Stevens Point, Wisconsin, 54481
Status
Address
Marshfield Clinic - Weston Center
Weston, Wisconsin, 54476
